Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization

Link to article at PubMed

bioRxiv. 2021 Mar 2:2021.03.01.433466. doi: 10.1101/2021.03.01.433466. Preprint.


The relative resistance of SARS-CoV-2 variants B.1.1.7 and B.1.351 to antibody neutralization has been described recently. We now report that another emergent variant from Brazil, P.1, is not only refractory to multiple neutralizing monoclonal antibodies, but also more resistant to neutralization by convalescent plasma (6.5 fold) and vaccinee sera (2.2-2.8 fold). The P.1 variant threatens current antibody therapies but less so the protective efficacy of our vaccines.

PMID:33688656 | PMC:PMC7941628 | DOI:10.1101/2021.03.01.433466

Leave a Reply

Your email address will not be published. Required fields are marked *